Reblozyl Side Effects
Generic name: luspatercept
Medically reviewed by Drugs.com. Last updated on May 10, 2024.
Note: This document contains side effect information about luspatercept. Some dosage forms listed on this page may not apply to the brand name Reblozyl.
Applies to luspatercept: parenteral injection for sub-q use.
Side effects include:
Most common (>10%) adverse reactions: fatigue, headache, musculoskeletal pain, arthralgia, dizziness/vertigo, nausea, diarrhea, cough, abdominal pain, dyspnea, COVID-19, peripheral edema, hypertension, hypersensitivity.
For Healthcare Professionals
Applies to luspatercept: subcutaneous powder for injection.
Hepatic
Very common (10% or more): Total bilirubin 2 or more times the upper limit of normal (ULN) (64%), alanine aminotransferase 3 or more times ULN (12%), aspartate aminotransferase 3 or more times ULN (11%)
Common (1% to 10%): Alkaline phosphatase 2 or more times ULN, direct bilirubin 2 or more times ULN[Ref]
Cardiovascular
Common (1% to 10%): Hypertension, deep vein thrombosis[Ref]
Nervous system
Very common (10% or more): Headache (26%), dizziness (11%)
Common (1% to 10%): Cerebrovascular accident[Ref]
Musculoskeletal
Very common (10% or more): Bone pain (20%), arthralgia (19%)[Ref]
Gastrointestinal
Very common (10% or more): Abdominal pain (14%), diarrhea (12%)
Common (1% to 10%): Nausea[Ref]
Metabolic
Common (1% to 10%): Hyperuricemia[Ref]
Respiratory
Very common (10% or more): Cough (14%)[Ref]
Immunologic
Common (1% to 10%): Influenza, viral upper respiratory infection[Ref]
Other
Very common (10% or more): Fatigue (14%)
Frequency not reported: Death (due to unconfirmed acute myelogenous leukemia)[Ref]
More about Reblozyl (luspatercept)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous erythropoiesis agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. (2019) "Product Information. Reblozyl (luspatercept)." Celgene Corporation
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.